The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $112.46, a high ...

Organon & Co. (NYSE:OGN), a global healthcare company spun off from Merck (NSE:PROR) in 2021, has established itself as a leader in women's health while expanding its presence in biosimilars and ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

We recently compiled a list of the 10 Best Dow Jones Dividend Stocks According to Wall Street Analysts. In this article, we ...

On Tuesday, Merck & Co Inc (NYSE:MRK ... analyst writes that Merck delivered strong operational performance across the majority of the company's market-leading (Oncology), attractively emerging ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Merck & Company (MRK – Research ... focusing on stocks such as Eli Lilly & Co, Amgen, and Gilead Sciences.

Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations. The company said that sales range reflects a decision to halt shipments of Gardasil ...